Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 14, 2022 08:00 ET | Source: Cocrystal Pharma, Inc.

Cocrystal Pharma to Present at the Noble Capital Markets’ NobleCon18 Conference

BOTHELL, Wash., April 14, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that James Martin, Chief Financial Officer and co-interim Chief Executive Officer, will present a...
April 12, 2022 08:00 ET | Source: Cocrystal Pharma, Inc.

Cocrystal Pharma Reports Favorable Preliminary Data from Phase 1 Initial Cohorts with CC-42344, a Novel, Broad-Spectrum Influenza A antiviral

CC-42344 administered orally as a single 100 mg or 200 mg dose in healthy adults showed a favorable safety and pharmacokinetic profile BOTHELL, Wash., April 12, 2022 (GLOBE NEWSWIRE) -- Cocrystal...
March 23, 2022 16:05 ET | Source: Cocrystal Pharma, Inc.

Cocrystal Pharma Reports 2021 Financial Results and Provides Updates on Development Programs and Milestones

Commenced enrollment in Phase 1 trial with orally administered, broad-spectrum antiviral agent CC-42344 for the treatment of pandemic and seasonal influenza AAdvanced COVID-19 programs with the goal...
March 22, 2022 08:00 ET | Source: Cocrystal Pharma, Inc.

Cocrystal Pharma to Participate in the Maxim Group 2022 Virtual Growth Conference

BOTHELL, Wash., March 22, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that management will participate in the 2022 Virtual Growth Conference, presented by Maxim Group...
March 10, 2022 08:00 ET | Source: Cocrystal Pharma, Inc.

Cocrystal Pharma Initiates Enrollment in Phase 1 Influenza A Study with Novel, Broad-Spectrum, Orally Administrated Antiviral CC-42344

BOTHELL, Wash., March 10, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces dosing of the first subjects in a Phase 1 clinical trial of healthy...
March 03, 2022 08:00 ET | Source: Cocrystal Pharma, Inc.

Cocrystal Pharma to Participate in Upcoming Investment Conferences

BOTHELL, Wash., March 03, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that management will participate in two upcoming investment conferences as follows: Q1 Investor...
January 27, 2022 08:00 ET | Source: Cocrystal Pharma, Inc.

Cocrystal Pharma Selects Two Lead Antiviral Drug Candidates for its COVID-19 Oral Drug Program

Novel broad-spectrum oral lead candidates CDI-988 and CDI-873, discovered using Cocrystal’s antiviral drug discovery platform, demonstrate superior in vitro potency against SARS-CoV-2 and activity...
January 06, 2022 08:00 ET | Source: Cocrystal Pharma, Inc.

Cocrystal Pharma Receives FDA Guidance to Advance Clinical Development of its COVID-19 Antiviral CDI-45205

Response to pre-IND briefing package supports pathway to initiating a Phase 1 clinical study in 2022 BOTHELL, Wash., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP)...
January 04, 2022 08:00 ET | Source: Cocrystal Pharma, Inc.

Cocrystal Pharma to Present at the H.C. Wainwright BioConnect Virtual Conference

BOTHELL, Wash., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces that management will present a company overview at the H.C....
December 22, 2021 08:00 ET | Source: Cocrystal Pharma, Inc.

Cocrystal Pharma’s COVID-19 Oral and Intranasal/Pulmonary Protease Inhibitors Exhibit Powerful In Vitro Potency Against the SARS-CoV-2 Omicron Variant

Antiviral activity now confirmed against SARS-CoV-2 and all variants of concernincluding Omicron, Delta, Alpha, Beta and Gamma BOTHELL, Wash., Dec. 22, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma,...